Skip to Content
MilliporeSigma
All Photos(3)

Documents

269476

Sigma-Aldrich

N-Acetylprocainamide

≥99%

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Linear Formula:
4-(CH3CONH)C6H4CONHCH2CH2N(C2H5)2
CAS Number:
32795-44-1
Molecular Weight:
277.36
MDL number:
MFCD00009052
UNSPSC Code:
12352100
PubChem Substance ID:
24856329
NACRES:
NA.22

Quality Level

200

assay

≥99%

form

solid

mp

138-140 °C (lit.)

solubility

soluble 1%, clear, colorless to faintly yellow (1N HCl)

SMILES string

CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1

InChI

1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)

InChI key

KEECCEWTUVWFCV-UHFFFAOYSA-N

Related Categories

General description

The relaxant effects of N-acetylprocainamide on bovine tracheal smooth muscle was studied.

Application

N-acetylprocainamide (NAPA) was used as a model drug in the study of establishing a quantitative approach to predict the renal clearances of basic drugs using N-1-methylnicotinamide (NMN).

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoo-Seong Jeong et al.
Pharmaceutics, 11(3) (2019-03-09)
Previous observations demonstrated that cimetidine decreased the clearance of procainamide (PA) and/or N-acetylprocainamide (NAPA; the primary metabolite of PA) resulting in the increased systemic exposure and the decrease of urinary excretion. Despite an abundance of in vitro and in vivo
M Boucher et al.
Journal of autonomic pharmacology, 18(2), 83-87 (1998-09-08)
1. The cardiac anticholinergic effects of procainamide (1 mg kg(-1) min(-1)) and its N-acetylated metabolite (NAPA) at equimolar dose (1.16 mg kg(-1) min(-1)) were studied using in vivo experimental pharmacological and in vitro radioligand binding studies. 2. Procainamide and NAPA
Brady S Moffett et al.
Pharmacotherapy, 26(12), 1687-1693 (2006-11-28)
To evaluate dosing and pharmacokinetic parameters of intravenous continuous-infusion procainamide in neonates, and to identify dosage regimens and factors leading to therapeutic procainamide levels and minimal adverse events. Retrospective, observational study. Pediatric hospital. . Twenty-one patients (seven preterm, 14 full
Application of capillary electrophoresis to the in vitro assessment of drug metabolism.
C M Hill et al.
Biochemical Society transactions, 23(3), 432S-432S (1995-08-01)
S D Nelson et al.
The Journal of pharmacology and experimental therapeutics, 273(1), 315-319 (1995-04-01)
Ischemic zone refractoriness and conduction delay respond differently to infarct healing and, hypothetically, may exert discordant influences on the electrophysiologic action of different classes of antiarrhythmic drugs. This study evaluated the influence of infarct healing on the electrophysiologic effects of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service